Evidence map›Paper›PMID 38419717›Full record

ReviewHeart international2023

Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations.

Ioannis Boutsikos, Eleftherios Beltsios, Bastian Schmack, Ioannis Pantazopoulos, Dimitrios G Chatzis

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heart international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Ioannis BoutsikosDepartment of Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Eleftherios BeltsiosDepartment of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Bastian SchmackDepartment of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Ioannis PantazopoulosDepartment of Emergency Medicine, Medical School, University of Thessaly, Larissa, Greece.
Dimitrios G ChatzisSchool of Medicine, European University of Cyprus, Nicosia, Cyprus.
Medizinische Hochschule Hannover · DEAlexandra Hospital · GREuropean University Cyprus · CYUniversity of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found to exert multiple cardioprotective effects. Large clinical trials showed their beneficial effects on patients with heart failure, reducing the rates of rehospitalizations and improving kidney function. The aim of this review is to summarize the latest evidence in the literature regarding the multiple effects of SGLT2 inhibitors on patients across the spectrum of cardiovascular diseases.

Indexed as

diabetes mellitusDiabetic cardiomyopathyglycosuriaheart insufficiencyrenal failuresodium glucose co-transporter 2 (SGLT2) inhibitors

Identifiers

PMID38419717
PMCPMC10898587
OpenAlexW4389511011

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.